---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336867"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2026-08-06T12:17:10+00:00"
generated_at: "2026-08-06T12:20:04.426102+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annexon reports all 10 GBS patients in FORWARD study improved within days on tanruprubart

## Summary
- All 10 patients showed rapid, clinically meaningful muscle strength improvement within 4 days of single 30 mg/kg infusion.
- Four bedbound patients walked with/without assistance between day 2 and day 8; one ventilated patient off ventilator within 4 days.
- Results consistent with Phase 3 data where ~90% improved by day 8; tanruprubart generally well-tolerated.
- BLA submission targeted for Q4 2026; MAA under EMA review; GBS has ~22,000 annual U.S./Europe cases and >$20B U.S. burden.
- CEO cites decade-long commitment to C1q-targeted approach for neuroinflammatory diseases.

## SEC filing metadata
- accession: 0001193125-26-336867
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2026-08-06T12:17:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/0001193125-26-336867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/d159969d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336867
- JSON: https://secwatch.observer/filing/0001193125-26-336867.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.